ArticleAmerican journal of respiratory and critical care medicine2023
Antiviral Responses of Tissue-resident CD49a
Article in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial.Open forum infectious diseases · 2025Trial
- Rbp-Jκ controls NK cell late maturation and migration via chromatin landscape remodeling.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Targeting Microglial CD49a Inhibits Neuroinflammation and Demonstrates Therapeutic Potential for Parkinson's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Genetic and Molecular Interconnections Between Chronic Obstructive Pulmonary Disease and Osteoporosis: Insights from Single-Cell and Mendelian Randomization Analyses.International journal of chronic obstructive pulmonary disease · 2026Article
- Natural killer cells in the lung: novel insight and future challenge in the airway diseases.ERJ open research · 2025Review
- Omega-3 Polyunsaturated Fatty Acids in Chronic Obstructive Pulmonary Disease Patients with COVID-19: A Review.Current nutrition reports · 2025Review
- Review
- Lung-resident lymphocytes and their roles in respiratory infections and chronic respiratory diseases.Chinese medical journal pulmonary and critical care medicine · 2024Review
- Human tissue-resident NK cells in the lung have a higher glycolytic capacity than non-tissue-resident NK cells in the lung and blood.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Review
- Immune cell trafficking: a novel perspective on the gut-skin axis.Inflammation and regeneration · 2024Review
- Mitochondria-Targeted Antioxidants as a Therapeutic Strategy for Chronic Obstructive Pulmonary Disease.Antioxidants (Basel, Switzerland) · 2023Review
- Welcome to the Neighborhood: Tissue-Resident Lung Natural Killer Cells in Chronic Obstructive Pulmonary Disease and Viral Infections.American journal of respiratory and critical care medicine · 2023Article
- ProbioticInternational journal of molecular sciences · 2022Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.